5. Conclusion
In all studies included in this meta-analysis, LBBAP in patients with
HFmrEF was feasible and safe. In the pooled analysis, LBBAP was found to
significantly shorten the QRS duration and improve cardiac systolic
function in patients with an LVEF of 35–50%. This suggests that the
application of LBBAP as a resynchronization strategy for patients with
HFmrEF could be an acceptable option, especially in patients with both
HFmrEF and dyssynchrony where a decrease in LVEF is anticipated. A
randomized, prospective study is warranted to evaluate the effect of
LBBAP-CRT on patients with HF and an LVEF >35% and ≤35%.